Industry news
Impax Laboratories acquires generic drugs from Teva
Impax Laboratories, Inc. a specialty pharmaceutical company, announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. and affiliates of Allergan plc for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application for the generic equivalent to Concerta (methylphenidate hydrochloride) for an aggregate purchase price of $586 million.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins